Foundation Medicine Jan 10, 2023 Foundation Medicine, Karyopharm Therapeutics Partnering on Endometrial Cancer CDx Jan 4, 2023 FDA Approves Foundation Medicine Blood Test as CDx for Rozlytrek Dec 21, 2022 FDA Approves Foundation Medicine Assay as CDx for Certain NSCLC Therapies Nov 30, 2022 Addario Lung Cancer Medical Institute Begins Study Exploring KRAS Inhibitor Resistance Sep 21, 2022 Foundation Medicine, Day One Biopharmaceuticals to Develop CDx for Tovorafenib Sep 12, 2022 Relay Therapeutics to Offer $300M in Common Stock; Inks CDx Deal With Foundation Medicine Sep 11, 2022 Repeat Biomarker Testing Informs Next Steps for Treatment-Resistant EGFR-Mutant NSCLC Patients Premium Aug 11, 2022 Novartis' Tabrecta Nets Full FDA Approval for NSCLC With METex14 Skipping Mutations Jul 14, 2022 Synthetic Control Arms Finding Stronger Footing in Precision Oncology Trials, Regulatory Submissions Premium Jun 30, 2022 Analysis of Tumor Mutation, Treatment Data Across Cancers Points to Predictive Biomarkers Jun 22, 2022 European Commission Approves Novartis MET Inhibitor Tabrecta for Advanced NSCLC Jun 10, 2022 Norway's Fledgling Precision Oncology Effort Finding Early Success Premium Jun 9, 2022 FDA Approves Foundation Medicine Test as CDx With Roche's Rozlytrek Jun 6, 2022 Foundation Medicine, Arvinas Partner to Develop CDx For Prostate Cancer Drug Jun 3, 2022 Foundation Medicine to Provide Comprehensive Genomic Profiling Tests in Lung Cancer Screening Trial May 9, 2022 Aadi Bioscience Inks NGS Lab Partnerships to Screen Solid Tumor Patients for Fyarro Trial Apr 22, 2022 EMA's CHMP Recommends Novartis' Tabrecta for Previously Treated NSCLC With METex14 Skipping Mutation Apr 12, 2022 In Sixth Year, Project GENIE Diversifying, Integrating Local Ancestry and Enhancing Clinical Data Premium Mar 22, 2022 FDA Approves Merck's Keytruda for MSI-H, dMMR Endometrial Cancer With Roche CDx Mar 17, 2022 FDA Approves FoundationOne CDx for EGFR Inhibitors to Identify EGFR Mutations in NSCLC Load More Breaking News Flare Therapeutics Raises $123M in Oversubscribed Series B Funding Round William Blair Initiates Coverage of MDxHealth With Outperform Rating White House Report Outlines Goals to Advance Genomic Research, Precision Therapy Development In Brief This Week: Fore Biotherapeutics, RayzeBio, Gilead Sciences, Atossa Therapeutics Bayer to Assess Nubeqa in High-Risk, Early-Stage Hormone-Sensitive Prostate Cancer BridgeBio Begins Phase I/II Study of SHP2 Inhibitor, Opdivo in KRAS-Mutant Solid Tumors
